1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
First Financial Corporation said Chief Financial Officer Rodger A. McHargue will retire effective December 31, 2026, and its Board appointed Senior Vice President and Director of Finance Paul D. Nungester, Jr. to succeed him effective January 1, 2027. The filing also describes Nungester's employment agreement, which includes a $375,000 base salary and severance terms tied to a change in control.
McHargue, who has served as CFO since 2010, retires effective December 31, 2026.
Nungester, age 52, joined the company on August 10, 2026 and becomes CFO effective January 1, 2027.
Nungester's employment agreement runs through June 30, 2028 and sets a base salary of $375,000 per year.
Change-in-control severance equals 2.0 times the sum of base salary, prior-year bonuses and benefit reimbursements.
Upexi reported results for the fiscal year ended June 30, 2026, in a press release furnished as Exhibit 99.1. Total revenue rose to about $25.0 million from $15.8 million, but the net loss grew to $246.1 million, or $3.87 per share, from $13.7 million, or $1.73 per share, mainly due to $195.1 million of unrealized losses on digital assets, so shareholders face a much larger reported loss despite higher revenue.
Total revenue was about $25.0 million for fiscal 2026, compared with $15.8 million for fiscal 2025; digital asset revenue totaled $17.4 million.
Net loss was $246.1 million, or $3.87 per share, versus $13.7 million, or $1.73 per share, a year earlier, driven by $195.1 million of unrealized losses on digital assets.
General and administrative expenses rose to $26.4 million from $11.9 million, primarily reflecting the build-out of the treasury strategy.
Subsequent to year-end, the credit facility with BitGo Prime, LLC was amended to reduce the interest rate from 11.5% to 7.5% per year.
CO2 Energy Transition Corp. said its non-binding letter of intent for an initial business combination expired after the parties chose not to extend the September 14, 2026 deadline for a definitive agreement. Nasdaq also approved moving the company's units, warrants, rights and common stock from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 16, 2026. The company said it continues talks with the other party and is evaluating other opportunities.
Non-binding letter of intent, announced July 17, 2026, expired after the parties did not extend the September 14, 2026 deadline
Company continues discussions with the other party and is evaluating other potential business combinations
Nasdaq approved transfer to the Nasdaq Capital Market on September 14, 2026; transfer effective at market open September 16, 2026
Hub Group said Nasdaq issued a Staff Delisting Determination on September 16, 2026, because the company has not filed its 2025 Form 10-K or its Forms 10-Q for the quarters ended March 31 and June 30, 2026. The company intends to appeal to a Nasdaq Hearings Panel and to seek an extended stay, but the filing says there is no assurance the stay will be granted, and the determination could lead to trading suspension.
Nasdaq issued the Staff Determination on September 16, 2026, after the filing deadline of September 14, 2026, the last day of a 180-day extension.
The determination has no immediate effect on trading, but a hearing request must be made by September 23, 2026.
A hearing request automatically stays suspension for 15 days; if the Hearings Panel does not grant a further stay, Class A common stock would be suspended at the end of that period.
Hearings are typically scheduled about 30 to 45 days after the hearing request.
Rexford Industrial completed the $1.2 billion sale of a 22-property industrial portfolio to an affiliate of EQT Real Estate on September 16, 2026. The company said the deal is part of a $2.0 billion non-core disposition program and that it reaffirmed its 2026 guidance, which does not show a change in direction for headline results.
Portfolio of 22 industrial properties totaling 5.2 million rentable square feet sold for approximately $1.2 billion before credits, prorations and closing adjustments
Year-to-date dispositions total $1.5 billion, within the full-year 2026 disposition guidance range of $1.5 billion to $2.0 billion
Quarter to date, $485 million of debt repaid and $205 million of common stock repurchased; company reaffirmed 2026 guidance from its July 23, 2026 earnings release
Pathward Financial said President Anthony Sharett resigned from his roles as President of the company and of its subsidiary Pathward, N.A., to pursue other opportunities. The company plans to implement its succession plan and reorganize the President's responsibilities among existing executives.
Sharett notified the company of his resignation on September 14, 2026; it takes effect October 23, 2026.
The company intends to implement its succession plan; no successor is named in the filing.
Sharett previously served as chief legal and compliance officer, general counsel and corporate secretary.
Loop Industries said its Board of Directors has formed a Strategic Alternatives Committee, following the appointment of Jeff Geygan as Chairman and the separation of the Chairman and CEO roles. The committee's immediate priority is securing the capital contribution and project-financing structure for the planned India joint venture, and it will evaluate options that include a potential sale, merger or going-private transaction. The company said no decision has been made, no timetable has been set, and there is no assurance the review will lead to any transaction.
The Board formed the Strategic Alternatives Committee, announced in a press release dated September 17, 2026.
The immediate priority is securing Loop's required capital contribution for the India joint venture through project-level debt, strategic capital, equity financing or a combination.
Options under review include strategic investments, licensing, regional joint ventures, business combinations, and a potential sale, merger or going-private transaction.
No specific alternative has been chosen and no timetable has been established; the company does not intend to comment further unless the Board approves a specific course of action.
Axe Compute agreed on September 11, 2026 to sell Helomics, its last operating business from its former identity as Predictive Oncology, to DataMeds AI (NASDAQ: MEDS). The sale closed the same day, and the company received DataMeds stock and a convertible note rather than cash. The filing says the sale completes Axe Compute's transition to a pure-play neocloud GPU-as-a-Service company.
Consideration: 636,328 DataMeds common shares, equal to 19.99% of DataMeds shares outstanding before closing, plus a $1,363,672 convertible note with a $1.00 per share conversion price.
The shares and conversion shares are restricted securities subject to a 12-month lock-up from the closing date.
Axe Compute must pay the remaining base rent on two Pittsburgh, Pennsylvania leases used by Helomics through the current lease terms; other lease costs fall to DataMeds and Helomics.
The company issued a press release on September 15, 2026 announcing completion of the sale.
Nasdaq notified Fifth Era Acquisition Corp I on September 14, 2026 that it does not meet the 400 Total Holders requirement for continued listing on the Nasdaq Global Market. Nasdaq says this is a deficiency notice, not an imminent delisting, and the listing and trading of the company's securities are not currently affected.
Nasdaq Listing Rule 5450(a)(2) requires at least 400 Total Holders for continued listing on the Nasdaq Global Market
The company has until October 29, 2026 to submit a plan to regain compliance
If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days from the date of the notice
The company may consider transferring its securities to The Nasdaq Capital Market
Lisata Therapeutics acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 shares of common stock and 211,365.213 shares of Series C convertible preferred stock to Marea stockholders. A concurrent private placement is expected to raise about $225 million in gross proceeds, and the filing says pre-transaction Lisata stockholders will hold about 2.39% of the company's common stock after the financing, which substantially dilutes existing holders.
Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders; each preferred share converts into 1,000 common shares, subject to Lisata stockholder approval
Concurrent private placement with a gross value of about $225 million; the investors will receive Series C preferred shares at about $1,491.37 per share
Post-financing ownership: pre-transaction Lisata holders about 2.39%, former Marea holders about 59.54%, private placement investors about 38.07%
Lisata's CEO is Dr. David J. Mazzo; Dr. Josh Lehrer was newly appointed President and Chief Operating Officer of Lisata
Two Caesars directors, Jesse Lynn and Ted Papapostolou, resigned from the board effective immediately on September 16, 2026, and the Icahn Group waived its right to appoint replacements. The Federal Trade Commission issued a Second Request on September 14, 2026, which extends the HSR Act waiting period for the pending merger with Fertitta Entertainment, so completion is further delayed and remains subject to regulatory review and other closing conditions.
Jesse Lynn and Ted Papapostolou resigned from the board effective immediately, as of September 16, 2026.
The Icahn Group waived its right to appoint replacement directors under the agreement dated March 17, 2025.
The FTC issued a Second Request on September 14, 2026; the waiting period runs until 30 days after substantial compliance by each party, unless extended or ended sooner.
The proxy deadline for internet or telephone voting is 11:59 p.m. Eastern Time on September 21, 2026.
PetMed Express (PetMeds) appointed Jeff Willard as Chief Executive Officer, President and a director, effective September 28, 2026, succeeding Leslie C.G. Campbell, who has served as Interim CEO and President since August 2025. Campbell is also retiring as Board Chair and leaving the Board on the same date, and Justin Mennen will become Chair. The filing sets Willard's initial base salary at $550,000 and a three-year initial employment term, a significant change in the company's top leadership.
Jeff Willard, age 56, was CEO of Stewart-MacDonald from November 2024 to September 2026; the Board approved his appointment on August 27, 2026.
Initial base salary of $550,000, target annual bonus of 75% of base salary, and a $120,000 signing bonus.
Justin Mennen, currently Lead Independent Director, succeeds Leslie C.G. Campbell as Chair effective September 28, 2026.
Campbell will remain as a full-time Strategic Advisor for 60 days following Willard's arrival.
Surgery Partners completed the sale of its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026, receiving aggregate consideration of about $796.6 million, with proceeds mainly used to pay down debt. Pro forma figures show lower revenue and a larger net loss attributable to the company for the periods presented, while management expects the deal to be accretive to adjusted earnings growth on an annual basis and to reduce balance sheet leverage. The company also updated its 2026 guidance to remove the sold hospitals' contribution for the rest of the year.
Sale closed September 14, 2026; gross proceeds of $797 million and $587 million in net cash proceeds at closing, subject to post-closing adjustments.
Balance sheet leverage, as defined in the credit agreement, is expected to improve by 30 basis points from 4.4x at the end of Q2 2026.
Updated 2026 guidance: revenue of $3.08 billion to $3.18 billion and Adjusted EBITDA of at least $489 million.
Pro forma net loss attributable to Surgery Partners was $69.2 million for the six months ended June 30, 2026, versus $50.9 million as reported; estimated gain on sale is $16.4 million.
Franklin BSP Realty Trust's board reappointed Richard Byrne as Chief Executive Officer effective September 16, 2026, succeeding Michael Comparato, who resigned on September 15, 2026. The company said Comparato is stepping back from day-to-day executive responsibilities, and Byrne will also remain Chairman of the Board. For shareholders, this is a change in the company's top executive role at an externally managed real estate investment trust.
Richard Byrne reappointed CEO effective September 16, 2026; he previously served as CEO from 2016 to February 2026 and continues as Chairman.
Michael Comparato resigned as CEO on September 15, 2026, and will serve as an advisor to Benefit Street Partners L.L.C.; the press release describes a Senior Advisor role at BSP through 2027.
Jerome S. Baglien, CFO and COO, was appointed Co-President alongside Brian Buffone and will lead BSP's Commercial Real Estate Debt platform.
Duke Robotics appointed Avi Levin as Chief Financial Officer, effective October 1, 2026, replacing Shlomo Zakai, who will continue to provide consulting services to the company. The filing sets out Levin's pay, which includes a monthly base salary and a future grant of stock options, so shareholders can see the compensation terms tied to the new finance chief.
Avi Levin becomes CFO on October 1, 2026; Shlomo Zakai ceases to be CFO at that time and is expected to continue as a financial and corporate consultant.
Levin's gross monthly base salary is NIS 52,250 (approximately $17,227), with a gross monthly expense allowance of NIS 2,500 (approximately $824).
The Board approved a future grant of options to buy up to 35,000 shares, with a six-year term and a strike price equal to the average closing price over the 30 trading days before the grant date.
Levin previously served as CFO of RAD Data Communications (2023 to 2025), BlackSwan Technologies (2021 to 2023) and Ability Inc. (2015 to 2020).
Colony Bankcorp said on September 17, 2026 that it has received all required regulatory approvals for its merger with First Reliance Bancshares. The deal still needs shareholder approvals from both companies, with special meetings set for October 14, 2026, and the 8-K gives an expected closing date of November 1, 2026.
All required regulatory approvals received, announced September 17, 2026
Shareholder special meetings for both companies scheduled for October 14, 2026
Expected closing date of November 1, 2026, pending shareholder approvals and other customary conditions
Deal valued at approximately $163 million; combined company to have about $5 billion in total assets
On September 15, 2026, Hallador Energy and subsidiary Turtle Creek Gas Holdings closed a $600 million senior secured term loan with Kennedy Lewis Investment Management, with $550 million funded at closing. The company says the loan will fund turbine payments, development costs and construction of the 460-megawatt Turtle Creek gas project, which has an expected total cost of less than $800 million, but borrowings carry high interest rates and are secured by substantially all company and subsidiary assets.
$600 million senior secured term loan, with $550 million funded at closing and a $50 million delayed draw available for 12 months
Interest is 3.5% cash plus SOFR plus 4.50% payable in kind before commercial operation, then SOFR plus 8.00% in cash after operation begins
Loan matures three years after closing, with a two-year extension option requiring a 3.0% extension fee
Covenants include minimum unrestricted cash of $10 million starting with the test period ending December 31, 2026
Aethlon Medical and private biotech North Immunology signed a merger agreement in which North Immunology becomes a wholly owned subsidiary of Aethlon and the combined company is renamed North Immunology, Inc. Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, while Aethlon stockholders also receive contingent value rights tied to proceeds, if any, from a sale or other monetization of its legacy Hemopurifier business.
Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company; North Immunology holders, including Private Placement investors, about 95.25%
Concurrent private placement expected to provide about $180 million, including about $34 million from converted notes; closing requires at least $175 million in proceeds
Expected to close in the first quarter of 2027; either party may terminate if not closed by June 17, 2027; termination fees are $300,000 (Aethlon) and $2,000,000 (North Immunology) in specified cases
Combined company expected to trade on Nasdaq Capital Market under ticker NRTX and be led by North Immunology's CEO
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.